Investors are positioning themselves ahead of November, according to Daniel Pearlstein, research analyst with Dundee Capital Markets.
The Canadian Federal Government’s Task Force on Marijuana Legalization and Regulation is expected to report back to the government in November before legislation is introduced in the spring of 2017. It is anticipated that the proposed changes will include both medical and recreational marijuana.

Analysts weigh in

Pearlstein said, “… I think a lot of investors are trying to get ahead of these catalysts that may imply supply and distribution for a recreational market, because the downside is even a two to three billion dollar market where you know the players are already in the race, they’re right here today.” He adds, “Even if recreational does not happen at all.”

Jason Zandberg of PI Financial shared the same sentiment on a note issued October 5, and says, “With the Canadian federal government expecting to introduce recreationally legal cannabis legislation next spring, those companies that are active in the medical MJ sector are poised to benefit.”

Canopy Growth hits a 52-week high

True enough, a number of cannabis stocks are trending upwards this week, and for good reason.
Canopy Growth (TSX:CGC) jumped to a record high of $5.80 at 10am on October 6, after announcing that its subsidiary, Tweed Inc., is releasing Leafs By Snoop, a line of marijuana products in partnership with rapper and “cannabis connoisseur” Snoop Dogg. Mark Zekulin, president of Tweed, said in the release. “We’re welcoming a cannabis culture icon into the Canadian industry.”
Canopy also has a Buy rating from PI Financial, with a 12-month target of C$5. In its recent research note, PI Financial says that “near term catalysts could light stock up.”

Some marijuana stocks registering gains this week

Vancouver-based Aurora Cannabis (TSXV:ACB) is up 12 percent, closing its second day of trading on the TSXV at $2.00 per share. Aurora Cannabis commenced trading on the TSXV on October 5, and operates a 55,200 square foot production facility in Mountain View County, Alberta, with plans to open a 600,000 square foot facility next year.

Ontario-based Aphria Inc. (TSXV:APH) hit a high of $4.02 and ended the day at $3.32. The stock is up 160 percent year to date. Aphria touts itself as “the first public licenced medical cannabis producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.”
OrganiGram Holdings (TSXV:OGI) hit a high of $2.42 earlier in the day, and closed at $2.02. The stock is up 115 percent year to date. Organigram’s production facility and R&D is located in Moncton, New Brunswick, with a current production capacity of 2,700 kg/yr.
Mettrum Health (TSXV:MT) hit $4.24 earlier on October 6, and closed at $3.66. The stock is up 93 percent year to date. Mettrum has three licensed facilities in Ontario with an annual production capacity of approximately 12,000 kilograms. Economist Michael Decter has listed Mettrum as a “Top Pick”.
Investors should certainly take note that analysts predict the positive rally to continue on until the Fed’s Task Force proposes changes to the current marijuana regulations. Continue to watch this space to see future developments.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Mettrum Health is a client of the Investing News Network. This article is not paid-for content.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less